SIG
AVDL

Stanford Investment Group’s Avadel Pharmaceuticals AVDL Stock Holding History

Stanford Investment Group’s Portfolio AVDL Stock Details AVDL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q1 		– Sell
-11,790
Closed -$122K – 18
2016
Q4 		$122K Hold
11,790
– – 0.06% 76
2016
Q3 		$146K Hold
11,790
– – 0.07% 69
2016
Q2 		$127K Hold
11,790
– – 0.06% 79
2016
Q1 		$130K Hold
11,790
– – 0.07% 77
2015
Q4 		$144K Hold
11,790
– – 0.08% 73
2015
Q3 		$192K Hold
11,790
– – 0.14% 49
2015
Q2 		$250K Hold
11,790
– – 0.19% 41
2015
Q1 		$212K Hold
11,790
– – 0.17% 45
2014
Q4 		$202K Buy
+11,790
New +$168K 0.17% 48

Other funds holding AVDL

BC
Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
JHIU
Janus Henderson Investors US Denver, Colorado $122B AUM 18.26% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $344B AUM 42.99% 1-Year Est. Return
JGC
J. Goldman & Co New York $3.87B AUM 46.94% 1-Year Est. Return
BCM
Brown Capital Management Baltimore, Maryland $500M AUM 25.3% 1-Year Est. Return

Stanford Investment Group's AVDL Position: Q1 2017 in Review

Stanford Investment Group sold out of Avadel Pharmaceuticals (AVDL) in Q1 2017, closing a stake of 11,790 shares — an estimated $122K sold.

Stanford Investment Group first reported a position in AVDL in Q4 2014 and held it in 9 quarters. The position peaked at $250K in Q2 2015. 74 funds tracked by Wall St. Rank hold AVDL as of Q1 2017.

  • Stanford Investment Group reported no remaining Avadel Pharmaceuticals position as of Q1 2017 after selling out during the quarter.
  • Stanford Investment Group sold 11,790 Avadel Pharmaceuticals shares in Q1 2017, an estimated $122K.
  • Stanford Investment Group first reported a position in Avadel Pharmaceuticals in Q4 2014 and held it in 9 quarters.
  • Stanford Investment Group's Avadel Pharmaceuticals position peaked at $250K in Q2 2015.
  • 74 funds tracked by Wall St. Rank held Avadel Pharmaceuticals as of Q1 2017.

Based on Stanford Investment Group's 13F filing for Q1 2017.